This is a summary of the European public assessment report (EPAR) for Izba. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Izba. For practical information about using Izba, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
Decrease of elevated intraocular pressure in adult patients with ocular hypertension or open\-angle glaucoma (see section 5\.1\). Decrease of elevated intraocular pressure in paediatric patients aged 3 years to \< 18 years with ocular hypertension or paediatric glaucoma.
Therapeutic Area (MeSH)
ATC Code
S01EE04
ATC Item
N/A
Pharmacotherapeutic Group
N/A
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| travoprost | N/A | travoprost |
EMA Name
Izba
Medicine Name
Izba
Aliases
N/ANo risk management plan link.
